According to the results of a Phase III clinical trial published in the Journal of Clinical Oncology, the chemotherapy drugs Gemzar® (gemcitabine) and Doxil® (pegylated liposomal doxorubicin) are similarly effective against ovarian cancer that is resistant to platinum-based chemotherapy.
To compare Doxil to Gemzar for the treatment of platinum-resistant ovarian cancer, researchers conducted a Phase III clinical trial among 195 women. All women had experienced cancer progression within six months of prior platinum-based therapy. The results suggest that Gemzar and Doxil are similarly effective against platinum-resistant ovarian cancer, and that Gemzar may be an acceptable alternative to Doxil in this setting.
The next logical step is to combine the two drugs. This is now being done in phase II studies but there no phase III trials yet. There are no guidelines recomemending combination treatment.
DR. W. Holloway, N. J. Finkler, L. P. Nye, G. E. Bigsby, B. H. Doxil and gemcitabine combination therapy for recurrent ovarian cancer: Results of a phase II trial.
Journal of Clinical Oncology, 2004 Vol 22, No 14S (July 15 Supplement), 2004: 5090
Mutch DG, Orlando M, Goss T et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. Journal of Clinical Oncology. 2007;25:2811-2818.
Ferranadina G, Paris I, Ludovisi M, et al. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival. Gynecologic Oncology. 2005;98:267-273.